United Therapeutics Reports Record $799M Revenue, $1B Buyback, Tyvaso DPI Growth

United Therapeutics reported strong financial performance in Q2 2025 with record revenues reaching approximately $798.6 million, marking a 12% year-over-year increase driven by robust sales of key products like Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Despite narrowly missing Wall Street revenue expectations, net income rose significantly to $309.5 million, supported by favorable Medicare changes and strategic pricing. The company authorized a substantial $1 billion share repurchase plan valid through March 2026, signaling confidence in its growth prospects. Analysts maintain an optimistic outlook with average price targets suggesting nearly 25-28% upside and predominantly 'buy' or 'outperform' ratings. United Therapeutics is also advancing its clinical pipeline, with upcoming Phase 3 data from the TETON 2 and ADVANCE OUTCOMES studies expected to fuel future growth. These factors underscore the company's strong commercial foundation, innovation strategy, and effective capital management that position it well for sustained long-term success.